Get the Stockscreener App
4.23
7.91%
0.31
After Hours:
4.25
0.02
+0.47%
Galectin Therapeutics Inc stock is traded at $4.23, with a volume of 1.85M.
It is up +7.91% in the last 24 hours and up +69.20% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$3.92
Open:
$3.96
24h Volume:
1.85M
Relative Volume:
4.39
Market Cap:
$278.57M
Revenue:
-
Net Income/Loss:
$-26.25M
P/E Ratio:
-10.32
EPS:
-0.4099
Net Cash Flow:
$-20.05M
1W Performance:
+49.73%
1M Performance:
+69.20%
6M Performance:
+4.96%
1Y Performance:
+68.53%
1-Day Range:
$3.8801
$4.37
1-Week Range:
$2.71
$4.37
52-Week Range:
$2.025
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
4.23 | 258.16M | 0 | -26.25M | -20.05M | -0.4099 |
VRTX
Vertex Pharmaceuticals Inc
|
480.18 | 120.61B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
620.14 | 65.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.65 | 53.02B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.17 | 39.26B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
178.17 | 36.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Galectin Therapeutics CMO Jamil Khurram sells $23,728 in shares By Investing.com - Investing.com Canada
Form 4 Galectin Therapeutics Inc For: 25 June By Investing.com - Investing.com Canada
Galectin (NASDAQ: GALT) CMO exercises options and sells 7,557 shares under 10b5-1 plan - Stock Titan
Galectin De-Risks Belapectin Path With FDA AlignmentSets Stage For Phase 3 Upside - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) and Gilead Sciences (GILD) - The Globe and Mail
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH - Yahoo Finance
Form 144 GALECTIN THERAPEUTICS INC For: 23 June By Investing.com - Investing.com Australia
Form 144 GALECTIN THERAPEUTICS INC For: 23 June - Investing.com UK
GALT stock surges 22% — on track for best day in over a year after FDA clears path for late-stage belapectin trial - MSN
GALT affiliate notifies sale of 8,125 shares (NASDAQ: GALT) - Stock Titan
Galectin Therapeutics (GALT) Announces FDA Agreement for Phase 3 Program - GuruFocus
GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial - Asianet Newsable
Galectin Therapeutics stock surges on FDA trial agreement - Investing.com
Galectin Therapeutics clears FDA Type C milestone, shares react on NASDAQ - Ad-hoc-news.de
GALT Reiterated by HC Wainwright & Co. -- Price Target Maintained at $11 - GuruFocus
Galectin Therapeutics (GALT) Receives FDA Feedback for Phase 3 T - GuruFocus
Galectin Therapeutics Shares Surge on Positive FDA Meeting, Phase 3 Trial Plans - marketscreener.com
Galectin Therapeutics (GALT) Receives FDA Feedback for Phase 3 Trial Preparation - GuruFocus
Galectin reaches FDA agreement on Phase 3 trial for belapectin - Investing.com
Galecti, FDA agree on Phase 3 trial for MASH drug (GALT:NASDAQ) - Seeking Alpha
Galectin Therapeutics Secures FDA Agreement for Phase 3 Belapectin Trial in MASH Cirrhosis and Portal Hypertension 1 – Minichart - Minichart
Galectin Advances Belapectin to Phase 3 After FDA Alignment - TipRanks
Galectin Therapeutics Reaches FDA Agreement on Phase 3 Endpoint and Regulatory Path for Belapectin Full Approval - Quiver Quantitative
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension - Yahoo Finance
Galectin Announces FDA Agreement on Phase 3 Endpoint and Q3 2026 Protocol Filing for Belapectin - TradingView
FDA backs Galectin (NASDAQ: GALT) belapectin Phase 3 plan in MASH - Stock Titan
GALT Stock Surges 22%On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial - Mena FN
Galectin Therapeutics Inc (GALT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Galectin Therapeutics Inc (GALT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Galectin Therapeutics Inc (GALT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Galectin Therapeutics Inc (GALT) Institutional Confidence - TradingKey
Galectin Therapeutics Inc (GALT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Galectin Therapeutics Inc (GALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Galectin Therapeutics Inc (GALT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Galectin Therapeutics Inc (GALT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Galectin Therapeutics Inc (GALT) Valuation: PE, PB & Fair Value Analysis - TradingKey
GALT Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Faces Investor ScrutinyQuarterly Profit Report - newsline.com
GALT Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances PipelineDividend Earnings Report - newsline.com
GALT Stock Price, Quote & Chart | GALECTIN THERAPEUTICS INC (NASDAQ:GALT) - ChartMill
Galectin Therapeutics CMO Jamil Khurram sells $1,761 in GALT stock By Investing.com - Investing.com India
Galectin Therapeutics CMO Jamil Khurram sells $1,761 in GALT stock - Investing.com
Galectin Therapeutics (GALT) CMO sells 568 shares after option exercise - Stock Titan
H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Galectin Therapeutics (GALT) Unveils New Insights from NAVIGATE Trial at EASL 2026 - GuruFocus
GALT Q1 2026 Earnings: EPS Misses Estimates as Clinical Development ContinuesPre-Earnings Setup - thelegaladvocate.com
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis - The Manila Times
Galectin Therapeutics (GALT) Holds Near $2.50 After Modest DeclineATR Stop - Newser
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
GALT Q1 2026 Earnings: Narrowed Loss Amid Clinical Progress, Stock RallyGuidance Accuracy Score - The Legal Advocate
Galectin Therapeutics (GALT) Q1 2026 Results Miss Estimates — EPS $-0.08 vs $-0.06Special Dividend Alert - Newser
Number of shareholders of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galectin Therapeutics Inc Stock (GALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jamil Khurram | Chief Medical Officer |
May 26 '26 |
Option Exercise |
1.23 |
568 |
699 |
568 |
| Jamil Khurram | Chief Medical Officer |
May 26 '26 |
Sale |
3.10 |
568 |
1,761 |
0 |
| ELDRED KARY | Director |
Feb 06 '26 |
Buy |
2.70 |
300 |
810 |
65,682 |
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Option Exercise |
0.00 |
84,000 |
0 |
916,592 |
| LEWIS JOEL | President and CEO |
Jan 06 '26 |
Sale |
3.58 |
37,698 |
134,853 |
832,592 |
| LEWIS JOEL | President and CEO |
Jan 05 '26 |
Sale |
3.91 |
27,731 |
108,342 |
870,290 |
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Sale |
4.20 |
18,571 |
77,939 |
898,021 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
67,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 05 '26 |
Sale |
3.90 |
25,732 |
100,298 |
27,968 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 06 '26 |
Sale |
3.67 |
20,354 |
74,695 |
7,614 |
0.23%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):